Skip to main content

Table 3 Univariable Cox regression for predictors of death or relapse of NPSLE in unmatched cohort and matched cohort after PSM

From: The influence of intrathecal injection of methotrexate and dexamethasone on neuropsychiatric systemic lupus erythematosus (NPSLE): a retrospective cohort study of 386 patients with NPSLE

 

Univariable Cox analysis in unmatched cohort

Univariable Cox analysis in matched cohort by PSM

Variables

HR (95%CI)

P valueb

HR (95%CI)

P valueb

Intrathecal therapy

0.55(0.3–0.99)

0.045*

0.50(0.27–0.95)

0.035*

Sex (Male)

0.34(0.08–1.39)

0.133

0.47(0.11–1.93)

0.291

System involvement of SLE

 Mucocutaneous

0.85(0.47–1.52)

0.583

0.90(0.48–1.68)

0.730

 Musculoskeletal

0.72(0.4–1.28)

0.265

0.78(0.42–1.44)

0.426

 Pulmonary involvement

1.46(0.62–3.43)

0.391

1.42(0.6–3.37)

0.431

 Cardiovascular involvement

1.9(1.04–3.48)

0.037*

2.05 (1.07–3.92)

0.031*

 Hematological involvement

1.08(0.6–1.94)

0.791

0.92(0.49–1.72)

0.797

 Lupus nephritis

1.28(0.71–2.3)

0.415

1.28(0.68–2.42)

0.446

 Serositis

2.2(1.16–4.17)

0.016*

2.01 (1.05–3.87)

0.035*

 SLEDAI-2K

1.01(0.97–1.04)

0.774

1.00(0.96–1.04)

0.847

Subtype of NPSLE

 Headache

0.5(0.23–1.07)

0.074

0.48 (0.21–1.09)

0.079

 Seizure disorder

2.05(1.15–3.66)

0.015*

2.03 (1.1–3.75)

0.024*

 Acute confusional state

3.73(2.03–6.87)

<0.001*

3.55 (1.86–6.78)

<0.001*

 Cerebrovascular disease

0.69(0.25–1.91)

0.471

0.84(0.3–2.36)

0.742

 Mood disorder

1.54(0.69–3.45)

0.295

1.94(0.86–4.38)

0.112

 Cognitive dysfunction

0.73(0.29–1.85)

0.507

0.89(0.35–2.28)

0.812

 Aseptic meningitis

0.39(0.05–2.86)

0.358

0.94(0.68–3.56)

0.906

 Anxiety

0.91(0.13–6.6)

0.924

1.25(0.17–9.08)

0.827

 Psychosis

0.71(0.72–4.63)

0.386

0.77(0.34–1.74)

0.528

 Myelopathy

1.83(0.72–4.63)

0.203

1.17(0.36–3.8)

0.795

 Demyelinating syndrome

1.68(0.52–5.43)

0.385

1.50(0.46–4.86)

0.503

 Guillain–Barré syndrome

1.45(0.2–10.54)

0.716

1.27 (0.17–9.27)

0.816

 Mononeuropathy

0(0–Inf)

0.997

0(0–Inf)

0.996

 Movement disorder

1.3(0.31–5.37)

0.716

1.43(0.35–5.95)

0.620

 Cranial neuropathy

1.11(0.27–4.58)

0.884

1.39(0.34–5.77)

0.649

 Plexopathy

3.86(0.53–28.15)

0.183

3.38(0.46–24.75)

0.231

 Polyneuropathy

1.72(0.68–4.35)

0.255

1.50(0.53–4.24)

0.441

Methylprednisolone pulse therapy

1.03(0.57–1.86)

0.922

0.96 (0.51–1.81)

0.911

CYC use

0.57 (0.32–1.00)

0.051

0.63 (0.34–1.16)

0.137

Increased ICPa

0.91(0.51–1.62)

0.753

0.78(0.42–1.46)

0.440

Increased levels of protein in CSFb

1.39(0.78–2.41)

0.258

1.47(0.8–2.72)

0.216

Abnormal CSF cytology

1.13(0.45–2.87)

0.793

1.17(0.41–3.3)

0.771

  1.  β2GP1 β2-Glycoprotein 1, ACL Anticardiolipin antibody, ICP Intracranial pressure, SLEDAI-2K Systemic Lupus Erythematosus Disease Activity Index 2000 scores
  2. aIncreased ICP refers to ICP that more than 180mmH2O
  3. bIncreased levels of protein in CSF refers to a level that more than 0.5g/L of CSF protein. Significant P values are noted with asterisks